Wantstats
Company ProfilePremium

GB Sciences, Inc.

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
GB Sciences, Inc. - Healthcare showcase

Year Founded & Workforce

2001

50 Employees

Industry

Healthcare

Services

Medical Cannabis Market
G

GB Sciences, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

GB Sciences, Inc. Overview

Company Headquarter: Nevada, US

Founded: 2001

Workforce: ~50

Company Working: GB Sciences, Inc. is a phytomedicine research and biopharmaceutical drug development company that converts the cannabis plant into medicines, therapies, and treatment-based drugs. The company’s novel drug development pipeline is built through collaborations with top university researchers and industry leaders in novel delivery and manufacturing processes. It operates numerous subsidiaries such as Growblox Life Sciences LLC (US), Growblox Sciences Puerto Rico LLC (US), GB Sciences Las Vegas, LLC (US), and GB Sciences Nevada, LLC (US).

Strategy

GB Sciences, Inc. is involved in the research & development of medicinal plants to improve its product line. It is focusing on launching unique solutions in the market. It is investing in R&D activities. Its products will help spur future growth in the region. Its strategy includes the proprietary PhAROS drug discovery platform and high-throughput screening of cell and animal models of specific disease processes in order to create rationally designed minimally essential mixtures.

Company Snapshot

$700.1M

Revenue

50

Employees

2001

Founded

SWOT Analysis

Strengths

  • Focus on innovative product launch
  • Collaborations with top university researchers and industry leaders

Weaknesses

  • Limited presence of the company
  • Need wide range of product portfolio

Opportunities

  • Expansion in untapped regions
  • Economic uptick and increasing customer spending
  • Collaborations with distributors

Threats

  • Stringent regulatory policies

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
May 2021AnnouncementGB Sciences, Inc. announced that the United States Patent and Trademark Office (USPTO) would issue US Patent No. 10,653,640 entitled “Cannabinoid-Containing Complex Mixtures for the Treatment of Neurodegenerative Diseases.”
March 2018AcquisitionGB Sciences, Inc. has signed a letter of intent (LOI) to purchase NevadaPURE’s Las Vegas operation

Product Offering

  • GB Sciences, Inc.
    • Medical Cannabis Market

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales fell from USD 700.1 Mn in 2020 to USD 327.8 Mn in 2022.
GB Sciences, Inc. — By Business Segment
Series (USD Mn)202020212022
Sales700.1354327.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →